News Progressive MS Trials May Need a ‘Tailored’ MRI Approach, Researcher Tells ACTRIMS 2016 Progressive MS Trials May Need a ‘Tailored’ MRI Approach, Researcher Tells ACTRIMS 2016 by Patricia Silva, PhD | February 19, 2016 Share this article: Share article via email Copy article link Dr. Daniel S. Reich with Johns Hopkins University is giving an oral talk on “MRI as an Outcome Measure in Progressive Multiple Sclerosis” at Friday’s ACTRIMS Forum 2016. This year’s meeting focuses on progressive MS, and runs through Saturday, Feb. 20, in New Orleans. Magnetic resonance imaging (MRI) has been the most widely adopted outcome measure in relapsing-remitting multiple sclerosis (RRMS) for decades, with its early success in small baseline-to-treatment trials seeking to reduce the incidence of contrast-enhancing lesions predicting its effectiveness in large Phase 3 trials focusing on clinical outcomes. The availability of a known clinical trial design has promoted the explosion of approved immunomodulatory treatments for people with this type of multiple sclerosis (MS), Dr. Reich reported. In contrast, no comparable proof-of-concept trial design exists for progressive MS studies, resulting in fewer effective large Phase 3 trials. In his afternoon talk, Dr. Reich, a professor of Radiology and Neurology at the Johns Hopkins School of Medicine, will present insights regarding why it has been so hard to resolve this problem for progressive MS patients. He also will outline the most encouraging imaging-based methods proposed to date, particularly on measurement of atrophy and MRI signal-intensity alterations that could be consistent with repair. Dr. Reich suggests there are three distinct options for the use of MRI in patients with progressive MS that might be considered “off the beaten track”: (1) MRI might be more valuable as an approach for improving progressive MS trials than as an outcome measure per se; (2) outcome measures for proof-of-concept trials should favor sensitivity above biological specificity; (3) screening of new therapies to be tested in progressive MS should be done first in early active disease. In his ACTRIMS’ abstract, Dr. Reich concluded, “unlike the situation in relapsing-remitting MS, progressive MS may not be conducive to a generic set of outcome measures. Rather, MRI methods may need to be tailored to what each specific therapy is broadly expected to achieve (e.g., prevention of neuronal loss, repair of damaged tissue, reduction of compartmentalized inflammation). As such, parallel studies of the same therapies, using similar imaging methods but in preclinical models, should be a high priority.” Print This Page About the Author Patricia Silva, PhD Patrícia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. Patrícia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags ACTRIMS, ACTRIMS Forum 2016, MRI, PPMS, progressive MS
April 25, 2024 Columns by Benjamin Hofmeister Finding safety while living with the constant threat of MS progression
April 25, 2024 News by Margarida Maia, PhD Having MS may marginally increase likelihood of cervical cancer: Study
April 25, 2024 News by Marisa Wexler, MS MS patients prefer Tysabri injection to intravenous infusion: Study